Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Trade Show

Ocular Therapeutixtm to Present at the Jefferies 2019 London Healthcare Conference


Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Donald Notman, Chief Financial Officer of Ocular Therapeutix, will give a company presentation on Thursday, November 21st at 8:40 a.m. GMT at the Jefferies 2019 London Healthcare Conference being held at the Waldorf Hilton in London, UK.

In addition to the presentation, the Company will host investor meetings at the conference. Investors attending the conference who are interested in meeting with Ocular Therapeutix management should contact their Jefferies representative.

A live webcast of the presentation can be accessed by visiting the Investors section of the Company's website at investors.ocutx.com. A replay of the webcast will be available on the Company's website for 90 days following the conclusion of the event.

About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology. Ocular Therapeutix's first commercial drug product, DEXTENZA®, is FDA-approved for the treatment of ocular inflammation and pain following ophthalmic surgery. Ocular Therapeutix has also begun a Phase 3 clinical trial evaluating DEXTENZA for the treatment of ocular itching associated with allergic conjunctivitis. OTX-TP (intracanalicular travoprost insert) is an intracanalicular insert in Phase 3 clinical development for the reduction of intraocular pressure in patients with primary open-angle glaucoma and ocular hypertension. The Company's earlier stage assets include OTX-TIC, an extended-delivery intracameral travoprost implant for the reduction of intraocular pressure in patients with glaucoma and ocular hypertension, as well as sustained release intravitreal implants for the treatment of retinal diseases. These intravitreal implants include OTX-TKI, containing a tyrosine kinase inhibitor (TKI), and, in collaboration with Regeneron, OTX-IVT, an extended-delivery protein-based anti-vascular endothelial growth factor (VEGF) trap. Ocular Therapeutix's first product, ReSure® Sealant, is FDA-approved to seal corneal incisions following cataract surgery.


These press releases may also interest you

at 22:58
One-day mobile collections for COVID-19 testing specimens are continuing this weekend and into early next week, with the University of Mississippi Medical Center, Mississippi State Department of Health, Mississippi Emergency Management Agency and...

at 22:10
CureApp, Inc. (Head Office, Chuo-ku, Tokyo; President and CEO, Kohta Satake, M.D.), developer of software as a medical device "Digital Therapeutics" mobile applications, has launched a Phase 3 multicenter, randomized comparative study (clinical...

at 21:45
LiveShop Inc., an e-commerce platform to enable local shops to sell easily to their local buyers, has decided to offer their platform to all sellers in the U.S. and U.K. Company announcement: With social distancing and stay-at-home directives in...

at 20:05
Technavio has been monitoring the artificial intelligence (AI) in construction market and it is poised to grow by USD 1.13 billion during 2019-2023. The report offers an up-to-date analysis regarding the current market scenario, latest trends and...

at 19:30
The "Loudspeakers Global Market Report 2020" report has been added to ResearchAndMarkets.com's offering. This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares,...

at 19:30
Trepp, a leading provider of information, analytics, and solutions to the structured finance, commercial real estate (CRE), and banking markets has released its quarterly report of bank portfolio loan performance in commercial real estate,...



News published on 14 november 2019 at 08:05 and distributed by: